Protalix Biotherapeutics, Inc. Announces Positive Phase I Clinical Trial Results for Oral GCD in Gaucher Disease Patients

Published: Oct 14, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CARMIEL, Israel, Oct. 14, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today initial positive results from its phase I clinical trial of oral glucocerebrosidase (GCD), or Oral GCD (PRX-112), in patients with Gaucher disease. In the trial, Oral GCD was well-tolerated, and active enzyme was detected in patients' blood circulation. Oral GCD is an orally available form of the plant cell-expressed enzyme, glucocerebrosidase or GCD, which is the same active substance as the Company's approved enzyme replacement therapy, ELELYSO™. Oral GCD is an active form of human glucocerebrosidase which is naturally encapsulated within the carrot cells in which it is produced.

Help employers find you! Check out all the jobs and post your resume.

Back to news